Artigos com autorizações de acesso público - Pardeep S. JhundSaiba mais
Não disponíveis em nenhum local: 8
Importance of cystatin C in estimating glomerular filtration rate: the PARADIGM-HF trial
P Tolomeo, JH Butt, T Kondo, G Campo, AS Desai, PS Jhund, L Køber, ...
European Heart Journal 44 (24), 2202-2212, 2023
Autorizações: US National Institutes of Health, British Heart Foundation
Expediting the benefits of sodium-glucose cotransporter-2 inhibitors for heart failure—there is no time for delay
GC Fonarow, CW Yancy
JAMA cardiology 6 (5), 507-508, 2021
Autorizações: British Heart Foundation
Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment
M Yang, T Kondo, IS Anand, RA de Boer, RT Campbell, L Køber, ...
European journal of heart failure, 2024
Autorizações: British Heart Foundation
Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON‐HF trial
H Lu, BL Claggett, M Packer, MA Pfeffer, CSP Lam, MR Zile, AS Desai, ...
European journal of heart failure, 2024
Autorizações: British Heart Foundation
Bedeutung der Herzinsuffizienz für Prävention, Therapie und Prognose des ischämischen Schlaganfalls
KG Häusler, M Endres, W Doehner
Aktuelle Neurologie 44 (04), 267-271, 2017
Autorizações: German Research Foundation, Volkswagen Foundation, Federal Ministry of …
Sex differences in cardiac structure and function following acute myocardial infarction: Insights from the PARADISE‐MI echocardiographic substudy
X Wang, MA Pabon, M Cikes, K Jering, W Mullens, L Kober, PS Jhund, ...
European Journal of Heart Failure, 2024
Autorizações: British Heart Foundation
Age-Adjusted Survival Extrapolations—Results May Differ From Those Generated by the Weibull Model—Reply
PS Jhund, KF Docherty, JJV McMurray
JAMA cardiology 7 (5), 570-570, 2022
Autorizações: US National Institutes of Health, American Heart Association
Reply: Pneumonia and the Bigger Picture of Infection in Heart Failure
L Shen, PS Jhund, JJV McMurray
Journal of the American College of Cardiology 78 (7), 760-761, 2021
Autorizações: British Heart Foundation
Disponíveis em algum local: 253
Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ...
New England Journal of Medicine 381 (21), 1995-2008, 2019
Autorizações: German Research Foundation
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
SL Kristensen, R Rørth, PS Jhund, KF Docherty, N Sattar, D Preiss, ...
The lancet Diabetes & endocrinology 7 (10), 776-785, 2019
Autorizações: British Heart Foundation
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis …
M Vaduganathan, BL Claggett, PS Jhund, JW Cunningham, JP Ferreira, ...
The Lancet 396 (10244), 121-128, 2020
Autorizações: US National Institutes of Health, Agence Nationale de la Recherche
Declining risk of sudden death in heart failure
L Shen, PS Jhund, MC Petrie, BL Claggett, S Barlera, JGF Cleland, ...
New England Journal of Medicine 377 (1), 41-51, 2017
Autorizações: US National Institutes of Health, US Department of Veterans Affairs …
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...
Jama 323 (14), 1353-1368, 2020
Autorizações: US National Institutes of Health, British Heart Foundation
Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum
LH Lund, B Claggett, J Liu, CS Lam, PS Jhund, GM Rosano, K Swedberg, ...
European journal of heart failure 20 (8), 1230-1239, 2018
Autorizações: Swedish Research Council
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI With ACEI to determine …
SL Kristensen, D Preiss, PS Jhund, I Squire, JS Cardoso, B Merkely, ...
Circulation: Heart Failure 9 (1), e002560, 2016
Autorizações: US National Institutes of Health
Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial
MN Kosiborod, PS Jhund, KF Docherty, M Diez, MC Petrie, S Verma, ...
Circulation 141 (2), 90-99, 2020
Autorizações: US National Institutes of Health, British Heart Foundation
Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
MMY Lee, KJM Brooksbank, K Wetherall, K Mangion, G Roditi, ...
Circulation 143 (6), 516-525, 2021
Autorizações: British Heart Foundation, UK Medical Research Council
Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF
JJV McMurray, AM Jackson, CSP Lam, MM Redfield, IS Anand, J Ge, ...
Circulation 141 (5), 338-351, 2020
Autorizações: British Heart Foundation
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left …
JJV McMurray, DL DeMets, SE Inzucchi, L Køber, MN Kosiborod, ...
European journal of heart failure 21 (5), 665-675, 2019
Autorizações: US National Institutes of Health
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo …
RR Holman, RL Coleman, JCN Chan, JL Chiasson, H Feng, J Ge, ...
The lancet Diabetes & endocrinology 5 (11), 877-886, 2017
Autorizações: National Institute for Health Research, UK
As informações de publicação e financiamento são determinadas automaticamente por um programa informático.